# United States DEA Cannabis-Related Documents Overview > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-related-regulatory-documents-dea/ > **Published:** 2026-02-23T13:02:46-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:14:38-04:00 > **Clinical Summary:** Explore cannabis-related regulatory documents by the DEA detailing federal scheduling and enforcement of marijuana and hemp products. --- CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyTHCHempSafety Why This Matters Understanding how the DEA classifies [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) is essential for patients and providers navigating the increasingly complex legal landscape between hemp, CBD, and controlled substances. Clinical Summary The DEA has published an updated collection of cannabis-related regulatory and scheduling documents, providing a consolidated federal reference for the current legal classification and enforcement framework surrounding marijuana and [hemp-derived cannabinoids](https://cedclinic.com/indiana-hemp-drug-ban-thc-product-access/). These documents detail the Controlled Substances Act scheduling criteria, enforcement guidance, and regulatory interpretations that shape how cannabis products are classified at the federal level. The resource is relevant as the November 2026 hemp ban approaches and the distinction between Schedule I, III, and exempt hemp products becomes increasingly consequential for clinicians and patients. Dr. Caplan’s Take “Every clinician recommending cannabinoid products needs to understand the DEA’s classification framework, because the legal landscape is about to shift dramatically and patient access depends on regulatory literacy.” Clinical Perspective The DEA’s newly consolidated cannabis documentation offers clinicians and researchers a critical reference point for understanding federal scheduling and regulatory compliance. These materials illuminate the evolving legal landscape that directly impacts patient access and clinical decision-making in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/). Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+United+States+Drug+Enforcement+Administration+Cannabis-Related+Documents+%40drcaplan&url=https%3A%2F%2Fwww.dea.gov%2Fresources%2Fdocuments%3Ff%255B0%255D%3Ddrug_categories%253A316) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.dea.gov%2Fresources%2Fdocuments%3Ff%255B0%255D%3Ddrug_categories%253A316) [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+United+States+Drug+Enforcement+Administration+Cannabis-Related+Documents+%E2%80%94+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.dea.gov%2Fresources%2Fdocuments%3Ff%255B0%255D%3Ddrug_categories%253A316) [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [📝 Read more on Substack](https://substack.com/@doctorapproved) [🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) 📰 Source: [https://www.dea.gov/resources/documents?f%5B0%5D=drug_categories%3A316](https://www.dea.gov/resources/documents?f%5B0%5D=drug_categories%3A316) Further Reading Cannabis Policy Wire[Policy Watch: 20 Regulatory Updates — March 10, 2026](https://cedclinic.com/dea-scheduling-synthetic-opioids-regulatory-updates-2026/) Research Digest[Daily Digest 2026-03-07](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Schedules of Controlled Substances: Rescheduling FDA Marijuana Products](https://cedclinic.com/fda-approved-cannabis-products-rescheduling-schedule-iii/) Learn about the rescheduling of FDA-approved marijuana products from Schedule I to Schedule III and its impact on permit requirements. [Read More](https://cedclinic.com/fda-approved-cannabis-products-rescheduling-schedule-iii/) [The Right Schedule for Marijuana Does Not Yet Exist](https://cedclinic.com/2026-cannabis-schedule-classification-challenges/) Explore scientific perspectives on the challenges of properly scheduling marijuana among controlled substances. [Explore Article](https://cedclinic.com/2026-cannabis-schedule-classification-challenges/) [CBD, Medicare, and the New FDA Enforcement Memo](https://cedclinic.com/medicare-coverage-cbd-products-fda-enforcement-memo/) Understand recent FDA enforcement updates affecting [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) and Medicare coverage implications. [Learn More](https://cedclinic.com/medicare-coverage-cbd-products-fda-enforcement-memo/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).